Skip to main content
. 2023 May 22;10(7):e433–e441. doi: 10.1016/S2352-3018(23)00081-4

Table 1.

Baseline characteristics of participants by study arm

Supplemental dolutegravir arm (n=53) Placebo arm (n=55) Total (n=108)
Demographics
Age, years 33 (28–38) 37 (33–44) 35 (31–40)
Sex
Female 19 (36%) 19 (35%) 38 (35%)
Male 34 (64%) 36 (65%) 70 (65%)
Weight, kg 56 (51–62) 55 (51–62) 56 (51–62)
BMI, kg/m2 20·0 (18·7–22·3) 20·2 (18·3–22·8) 20·1 (18·5–22·6)
HIV characteristics
HIV-1 RNA log10(log10 copies per mL) 5·1 (4·6–5·6) 5·2 (4·6–5·7) 5·2 (4·6–5·7)
≤100 000 copies per mL, n (%) 21 (40%) 21 (38%) 42 (39%)
>100 000 copies per mL, n (%) 32 (60%) 34 (62%) 66 (61%)
CD4 count (cells per μL) 197 (145–260) 183 (145–316) 188 (145–316)
≤200 27 (51%) 30 (55%) 57 (53%)
>200 26 (49%) 25 (45%) 51 (47%)
Baseline ART status, n (%)
ART naive 44 (83%) 44 (80%) 88 (81%)
First-line ART interrupted 9 (17%) 11 (20%) 20 (19%)
On ART <6 months before interruption 8 (15%) 5 (9%) 13 (12%)
On ART ≥6 months before interruption 1 (2%) 6 (11%) 7 (6%)
Tuberculosis characteristics
Diagnosis
Microbiological or histological (or both) 38 (72%) 39 (71%) 77 (71%)
Clinical or radiological (or both) 15 (28%) 16 (29%) 31 (29%)
Site
Pulmonary 40 (75%) 37 (67%) 77 (71%)
Extrapulmonary 10 (19%) 13 (24%) 23 (21%)
Disseminated 3 (6%) 5 (9%) 8 (7%)
Weeks on tuberculosis treatment at enrolment 8·0 (7·0–8·9) 8·0 (6·0–8·3) 8·0 (6·6–8·6)

Data are median (IQR) or n (%). Baseline was date of screening. ART=antiretroviral therapy.